MODULATION OF THE TH-17 CELL MEDIATED IMMUNE RESPONSES

• US 20100247547A1
• Filed: 05/29/2008
• Published: 09/30/2010
• Est. Priority Date: 05/29/2007
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Nurieva, Roza, Dong, Chen
• Application Number:
  US12/602,114
• Publication Number:
  US 20100247547A1
• Time in Patent Office: Days
• US Class Current: 424/158.100
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/244 Interleukins [IL]

Abstract

Methods of treating diseases or conditions associated with T_H 17 cell mediated immune response are provided where a subject is administered an effective amount of an agent that modulates the IL-21 signaling pathway so as to inhibit or induce the differentiation of T_H17 cells and/or the expression of IL-17, IL17-F, IL-22, and IL-21.

Claims

1. A method of treating a disease or condition associated with T_H17 cell mediated immune response in a subject in need thereof comprising the step of administering to the subject a therapeutically effective amount of an agent that modulates the IL-21 signaling pathway in an amount effective to modulate the differentiation of T_H17 cells or the expression of IL-17, IL17-F, IL-22, and IL-21.

2. A method of treating an inflammatory disease or condition in a subject in need thereof comprising the step of administering to the subject a therapeutically effective amount of an agent that modulates the IL-21 signaling pathway so as to modulate the differentiation of T_H17 cells.

3. The method of claim 2 wherein the agent that modulates is an IL-21 antagonist.

4. The method of claim 3 wherein the agent is an anti-IL-21 antibody.

5. A method of modulating the differentiation of T_H17 cells comprising the steps of modulating the IL-21 signaling pathway and the expression of IL-17, IL17-F, IL-22, or IL-21 by T_H17 cells whereby the generation of T_H17 cells is induced or inhibited and an immune response modified.